Resistance to Targeted Therapies in Multiple Myeloma, 1st ed. 2021
Resistance to Targeted Anti-Cancer Therapeutics Series, Vol. 22

Multiple Myeloma remains an incurable malignancy. As the disease progresses, it invariably becomes resistant to treatment and almost all patients develop refractory disease. There are multiple different types of targeted therapies and many of them are used in combination at different stages of disease. Targeted therapies that are approved to be used include Proteasome Inhibitors, Immunomodulatory Drugs and Monoclonal Antibodies. Second and third generations of these drugs are developed to overcome resistance and they have unique mechanism of actions. Targeted therapies that are undergoing clinical trials include CAR-T cells, bi-specific antibodies, vaccines, ubiquitin ligase inhibitors and BCL-2 inhibitors.

This book will help to develop an understanding of targeted therapies in Multiple Myeloma. Its goal is to provide a unique review of the mechanism of action and resistance of the many targeted therapies in Multiple Myeloma by leaders of the field. The book will be useful for students in medical science, clinicians, health professionals, scientists, pharmaceutical professionals, drug developers, and policy makers.

This book will provide an insightful knowledge of the biology of Multiple Myeloma, the mechanism of action and resistance of targeted therapies, application of biomarkers and genomics and possible strategies in overcoming resistance and future development. 

1. The role of targeted therapy in multiple myeloma

2. Lenalidomide

3. Pomalidomide

4. Mechanisms driving resistance to proteasome inhibitors bortezomib, carfilzomib and ixazomib in multiple myeloma

5. Daratumumab

6. Elotuzumab

7. Histone deacetylase inhibitors

8. Bone targeted therapies

9. New targeted therapies for multiple myeloma under clinical investigation

Dr Ling is a clinical and laboratory haematologist of Liverpool hospital and NSW Pathology in NSW, Australia. She is a conjoint senior lecturer of the South Western Sydney Clinical School of UNSW Sydney and Western Sydney University. She is the leader of the Haematology Research Group in Ingham Institute of Applied Medical Research. She is the lead clinician of the myeloma stream in Liverpool Hospital, NSW, Australia. She is a member of the Medical & Scientific Advisory Group (MSAG) of Myeloma Australia and the myeloma working party of the Australasian Leukaemia and Lymphoma Group. She is an investigator of industry sponsored and academic clinical trials.

Dr Ling received the degrees of MBBS and PhD from the University of Sydney. She is a fellow of the Royal Australasian College of Physicians and the Royal College of Pathologists of Australasia. She is a clinician scientist, with a focus on translational research in the mechanism of drug resistance in multiple myeloma. Her original research has been published in peer reviewed journals.

She organises the teaching program of biomedical science of the South Western Sydney Clinical School of UNSW Sydney. She is a research supervisor of undergraduate and post-graduate students of UNSW Sydney and Western Sydney University. She is an invited reviewer of manuscripts, grants and examiner of masters and PhD thesis.Steven Trieu is a PhD candidate at the University of New South Wales, focused on drug resistance in multiple myeloma. He has received a Bachelor of Advanced Science with First-Class Honours from the University of New South Wales and is currently a recipient of an Australian Government Research Training Program Scholarship.

Steven Trieu is a PhD candidate at the University of New South Wales, focused on drug resistance in multiple myeloma. He has received a Bachelor of Advanced Science with First-Class Honours from the Unive

Develops an understanding of targeted therapies in Multiple Myeloma

Provides a unique review of the mechanism of action and resistance

Features chapters written by internationally-based leaders in the field